Real-world experience of arbidol for Omicron variant of SARS-CoV-2

BACKGROUND: At a crucial time with the rapid spread of Omicron severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus variant globally, we conducted a study to evaluate the efficacy and safety of arbidol tablets in the treatment of this variant. METHODS: From Mar 26 to April 26, 2022, we...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Jingya, Li, Yong, Chen, Rong, Xu, Yanping, Yang, Qingyuan, Zhang, Haiqing, Yin, Zhengxin, Gu, Weiting, Hu, Jinsong, Chen, Li, Li, Jian, Ning, Guang, Cheng, Qijian, Zhou, Min, Qu, Jieming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9992600/
https://www.ncbi.nlm.nih.gov/pubmed/36910077
http://dx.doi.org/10.21037/jtd-22-980

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9992600/
https://www.ncbi.nlm.nih.gov/pubmed/36910077
http://dx.doi.org/10.21037/jtd-22-980

Ejemplares similares